Näytä suppeat kuvailutiedot

Exploiting Glutamine Consumption in Atherosclerotic Lesions by Positron Emission Tomography Tracer (2S,4R)-4-F-18-Fluoroglutamine

Miner Maxwell W. G.; Palani Senthil; Ravindran Aarthi; Knuuti Juhani; Roivainen Anne; Virta Jenni; Liljenbäck Heidi; Örd Tiit; Kaikkonen Mnna U.; Eskola Olli; Saraste Antti; Li Xiang-Guo

dc.contributor.authorMiner Maxwell W. G.
dc.contributor.authorPalani Senthil
dc.contributor.authorRavindran Aarthi
dc.contributor.authorKnuuti Juhani
dc.contributor.authorRoivainen Anne
dc.contributor.authorVirta Jenni
dc.contributor.authorLiljenbäck Heidi
dc.contributor.authorÖrd Tiit
dc.contributor.authorKaikkonen Mnna U.
dc.contributor.authorEskola Olli
dc.contributor.authorSaraste Antti
dc.contributor.authorLi Xiang-Guo
dc.date.accessioned2022-10-28T12:33:50Z
dc.date.available2022-10-28T12:33:50Z
dc.identifier.urihttps://www.utupub.fi/handle/10024/160430
dc.description.abstractIncreased glutamine metabolism by macrophages is associated with development of atherosclerotic lesions. Positron emission tomography/computed tomography (PET/CT) with a glutamine analog (2S,4R)-4-F-18-fluoroglutamine (F-18-FGln) allows quantification of glutamine consumption in vivo. Here, we investigated uptake of F-18-FGln by atherosclerotic lesions in mice and compared the results with those obtained using the glucose analog 2-deoxy-2-F-18-fluoro-D-glucose (F-18-FDG). Uptake of F-18-FGln and F-18-FDG by healthy control mice (C57BL/6JRj) and atherosclerotic low-density lipoprotein receptor-deficient mice expressing only apolipoprotein B100 (LDLR(-/-)ApoB(100/100)) was investigated. The mice were injected intravenously with F-18-FGln or F-18-FDG for in vivo PET/CT imaging. After sacrifice at 70 minutes post-injection, tracer uptake was analyzed by gamma counting of excised tissues and by autoradiography of aorta cryosections, together with histological and immunohistochemical analyses. We found that myocardial uptake of F-18-FGln was low. PET/CT detected lesions in the aortic arch, with a target-to-background ratio (SUVmax, aortic arch/SUVmean, blood) of 1.95 +/- 0.42 (mean +/- standard deviation). Gamma counting revealed that aortic uptake of F-18-FGln by LDLR(-/-)ApoB(100/100) mice (standardized uptake value [SUV], 0.35 +/- 0.06) was significantly higher than that by healthy controls (0.20 +/- 0.08, P = 0.03). More detailed analysis by autoradiography revealed that the plaque-to-healthy vessel wall ratio of F-18-FGln (2.90 +/- 0.42) was significantly higher than that of F-18-FDG (1.93 +/- 0.22, P = 0.004). Immunohistochemical staining confirmed that F-18-FGln uptake in plaques co-localized with glutamine transporter SLC7A7-positive macrophages. Collectively these data show that the F-18-FGln PET tracer detects inflamed atherosclerotic lesions. Thus, exploiting glutamine consumption using F-18-FGln PET may have translational relevance for studying atherosclerotic inflammation.
dc.language.isoen
dc.publisherFRONTIERS MEDIA SA
dc.titleExploiting Glutamine Consumption in Atherosclerotic Lesions by Positron Emission Tomography Tracer (2S,4R)-4-F-18-Fluoroglutamine
dc.identifier.urlhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.821423/full
dc.identifier.urnURN:NBN:fi-fe2022081154113
dc.relation.volume13
dc.contributor.organizationfi=PET tutkimus|en=PET Research|
dc.contributor.organizationfi=sisätautioppi|en=Internal Medicine|
dc.contributor.organizationfi=InFLAMES lippulaiva, tutkimus|en=InFLAMES Flagship, research|
dc.contributor.organizationfi=PET perustoiminta|en=PET Basic Operations|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, vsshp|
dc.contributor.organization-code2609810
dc.contributor.organization-code2607318
dc.contributor.organization-code2609820
dc.contributor.organization-code2607051
dc.converis.publication-id174794669
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/174794669
dc.identifier.jour-issn1664-3224
dc.okm.affiliatedauthorMiner, Maxwell
dc.okm.affiliatedauthorLiljenbäck, Heidi
dc.okm.affiliatedauthorPalani, Senthil
dc.okm.affiliatedauthorSaraste, Antti
dc.okm.affiliatedauthorLi, Xiang-Guo
dc.okm.affiliatedauthorVirta, Jenni
dc.okm.affiliatedauthorEskola, Olli
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.affiliatedauthorRoivainen, Anne
dc.okm.affiliatedauthorKnuuti, Juhani
dc.okm.discipline3126 Surgery, anesthesiology, intensive care, radiologyen_GB
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3126 Kirurgia, anestesiologia, tehohoito, radiologiafi_FI
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeJournal article
dc.publisher.countrySveitsifi_FI
dc.publisher.countrySwitzerlanden_GB
dc.publisher.country-codeCH
dc.relation.articlenumber821423
dc.relation.doi10.3389/fimmu.2022.821423
dc.relation.ispartofjournalFrontiers in Immunology
dc.year.issued2022


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot